DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Boston Scientific pays $336M; Boehringer Ingelheim acquires Abexxa Biologics; Oncology, RNA biotech 858 Therapeutics inks $60M Series A; Novartis acquires Arctos Medical Visit Post
2 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
3 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
4 ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System Visit Post
5 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
6 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
7 Abiomed’s Impella ECP; Helius’s PoNS Device; Smart Meter’s iGlucose BGM; XACT’s CT-Guided Percutaneous Procedures; BD’s Veritor At-Home COVID-19 Test; Delfi’s Liquid Biopsy Visit Post
8 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
9 Shape Therapeutics-Roche's Deal; AllStripes Raises $50M; Datavant-Real Chemistry's Partnership; BlueWillow's Nasal Vaccine Visit Post
10 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
11 Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents' DrugSorb-ATR; Fujifilm-Lunit collaboration Visit Post
12 FDA approval to Keytruda and Lenvima; FibroGen's Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palovarotene; Jazz Pharma’s Xywav; Seagen-RemeGen’s Cancer Medicine Visit Post
13 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
14 Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea's Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Visit Post
15 Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Visit Post
16 Nevro's Spinal Cord Stimulation; Boston's PINNACLE FLX; NuVasive's Modulus ALIF; J&J's VERITAS Vision System; Medtronic's DCB Catheter; AngelMed's Heart Attack Warning System Visit Post
17 Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal Visit Post
18 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
19 Fight Against the Antibiotic Resistance in the Uncomplicated Urinary Tract Infections Market Visit Post
20 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
21 MedTech Wrap Up Visit Post
22 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
23 Bayer's CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk's to get Prothena's ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle Visit Post
24 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
25 Arrowhead's ARO-ENaC Clinical Trial; Sartorius Acquires Stake in CellGenix; AGC Biologics's Cell & Gene Therapy; Sirnaomics Secures $105 Million Visit Post
26 MedTech Market Industry: Approval of Devices, Therapy Address Market Needs | Clinical Outcomes Create New Value Visit Post
27 Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future Visit Post
28 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
29 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
30 Age-related Hearing Loss Device Market Dynamics Expected to Step into Growth Quadrant Visit Post
31 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
32 Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M Visit Post
33 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
34 Latest Medtech Commercial, Regulatory and Clinical Updates For - Abbott, BD, CooperVision, Procyrion, TricValve, and others Visit Post
35 Amgen a leader in Undruggable Lung Cancer; Verrica's Skin Disease Drug Delays; Fennec's Faith in its Chemotherapy-Induced Hearing Loss Drug; Nexturn Bio's Acquisition of RosVivo Visit Post
36 Pieris-Genentech deal; Xilio inks deal with Merck; BMS taps Xencor's tech; GenSight's gene therapy reports partial recovery Visit Post
37 TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug Visit Post
38 MedTech Industry: Commercial, Regulatory and Clinical Updates Visit Post
39 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
40 Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids Visit Post
41 Abingworth & Alebund's Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal Visit Post
42 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
43 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
44 Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med Visit Post
45 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
46 Adagio Raises $336 M; Lyndra's Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian Cancer CAR-T Therapy Visit Post
47 Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO Visit Post
48 Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities Visit Post
49 Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M Visit Post
50 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
51 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
52 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
53 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
54 Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC Visit Post
55 GBT strikes a deal with Sanofi; Lilly's IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy Visit Post
56 Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acquires GenMark; FDA okays Melinta's Kimyrsa Visit Post
57 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
58 Overwhelming success of Gilead/Kite's Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio's antibody-drug failure; Roche discards Tecentriq for bladder cancer Visit Post
59 Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck Visit Post
60 Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva's $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China Visit Post
61 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
62 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
63 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
64 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
65 Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone Visit Post
66 Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials Visit Post
67 Aurinia's Lupkynis for Lupus; FDA Fast Track Designation for Toripalimab; Wren Therapeutics’ Financing; Merck’s Covid-19 Vaccine Program End Visit Post
68 Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline. Visit Post
69 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
70 Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Visit Post
71 Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off Visit Post
72 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
73 Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results Visit Post
74 Improving cancer immunotherapy; Senseonics' Eversense delayed; FDA acknowledges Alkermes' Resubmission; 3D breast ultrasound improves diagnosis Visit Post
75 A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica Visit Post
76 NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche's bispecific matches Eylea; Research Updates in Leukemia, solid tumors Visit Post
77 Agios' cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial Visit Post
78 Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders Visit Post
79 FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel Visit Post
80 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
81 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
82 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
83 BASE10 Collaboration; Advaxis Public offerings; Takeda's CABOMETYX Japan approval; TheraPharm Acquisition Visit Post
84 Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant's vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic Visit Post
85 Novartis' COVID-19 deal; Shattered hopes for Remdesivir; Lilly's R&D pact with Precision; Innovent's Humira Biosimilar Visit Post
86 Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M Visit Post
87 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
88 FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis's collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M Visit Post
89 Pfizer's COVID-19 Vaccine; Calliditas' NefIgArd trial; ViiV's HIV Prevention Treatment; Biogen’s Aducanumab Rejection Visit Post
90 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
91 Bristol Myers' psoriasis drug; GW Pharmaceuticals eyes US market for Nabiximols; Karyopharm's Xpovio; Kiadis USD 358M Buyout Visit Post
92 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
93 Bayer eyes AskBio’s Gene Therapies; Novartis' Iptacopan; Forma's IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic Visit Post
94 GSK's RSV vaccine; SparingVision's interest in gene therapy; InCarda's raise; BridgeBio's R&D deal Visit Post
95 Venclexta full approval; PBP1510 Orphan Status; Roche/ Genesis collab; Immunomodulators for COVID-19 Visit Post
96 Cyclerion's olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche's gene therapy pact; RayzeBio debuts with $ 45M to target tumors Visit Post
97 US/AZ deal; Alkermes' Schizophrenia drug; Innovent/Lilly's China market expansion; Rejection for Avenue Visit Post
98 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
99 MyoKardia buyout; Eidos acquisition; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin Visit Post
100 Brain's immune cells research update; Moderna's COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant's relugolix falls short in metastatic prostate cancer; Alnylam's lumasiran phase 3 result Visit Post
101 J&J 's COVID-19 vaccine; Roche, AC Immune's anti-Tau Alzheimer's drug; Silverback nets $85 M; Anokion's deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development Visit Post
102 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
103 Lilly's COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian's CD40L cell therapy Visit Post
104 While AZ resumes its COVID-19 vaccine trial in the UK; Merck and Gilead are busy making sizeable Breast cancer deals Visit Post
105 Pfizer-BioNTech COVID-19 vaccine trials; OncoImmune raises $56 M; Recursion Pharma nets $239 M; Breast cancer research updates Visit Post
106 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
107 Nestle to acquire Aimmune Therapeutics; Vir Bio & GSK's COVID-19 monoclonal antibody therapy; AstraZeneca's Farxiga scores goal in Phase III CDK trial Visit Post
108 Moderna's COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates Visit Post
109 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
110 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
111 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
112 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
113 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
114 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
115 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
116 AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid's DMD gene therapy trial Visit Post
117 Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai's Collaboration; A new study on averting heart attack Visit Post
118 AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Visit Post
119 Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Visit Post
120 Merck, Dewpoint's HIV Pipeline; Pfizer, BioNTech 's COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer Visit Post
121 Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates Visit Post
122 Regeneron's cocktail antibody, REGN-COV2; J&J's manufacturing-spree; ObsEva's Yselty top-line studies Visit Post
123 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
124 FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing Visit Post
125 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
126 Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114's Phase III result Visit Post
127 Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab's result; Orca raises $192M Visit Post
128 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
129 AbbVie & Genmab’s Collaboration; Lilly's antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent; Visit Post
130 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
131 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
132 Eli Lilly's COVID-19 Antibody trial; Approval for Oriahnn; Gilead's Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19 Visit Post
133 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
134 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
135 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
136 Moderna's COVID-19 Vaccine; Quidel's Lyra gets EUA from FDA; Neurotrope and Metuchen Pharma Announced Merger Agreement; FDA Approval to Rucaparib; Visit Post
137 Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ's anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost Visit Post
138 Mavacamten Phase III clinical trial, FDA nod for Ovarian cancer therapy, Dyno Therapeutics & Novartis Collaboration, Abbott's COVID-19 diagnostic kit Visit Post
139 Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic, Visit Post
140 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
141 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
142 In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up Visit Post
143 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
144 COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market Visit Post
145 Vir's drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines Visit Post
146 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
147 AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure Visit Post
148 Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19 Visit Post
149 Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies Visit Post
150 J&J's COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott's POC test; Cobra Bio raises $ 3.3 M Visit Post
151 FDA permits COVID-19 treatment, Roche's antibiotics pact, Moderna's vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million Visit Post
152 Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid Visit Post
153 Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial Visit Post
154 Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib Visit Post
155 JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19 Visit Post
156 Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment Visit Post
157 CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment Visit Post
158 Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine Visit Post
159 US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing Visit Post
160 Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust Visit Post
161 J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug Visit Post
162 Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma Visit Post
163 Immune cells for age-related diseases; Regeneron's antibody for 2019-nCoV; FDA nods for hydrogel injection Visit Post
164 First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed's shares Soares Visit Post
165 Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey Visit Post
166 Acceleron Pharma's drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson's disease Visit Post
167 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
168 Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102 Visit Post
169 Thumbs down to NKTR-181, Lilly expands its insulin armamentarium Visit Post
170 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
171 Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M Visit Post
172 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
173 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
174 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
175 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
176 Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition Visit Post
177 Acquisition of ArQule; Synthorx; and Zentalis nabs a raise Visit Post
178 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
179 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
180 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
181 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
182 Nordisk ties up with Dicerna; Pfizer's drug gets FDA nod Visit Post
183 AbbVie Sells bonds to Fund Allergan takeover Visit Post
184 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
185 Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences Visit Post
186 AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy Visit Post
187 AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood Visit Post
188 AZ announces positive results for durvalumab and tremelimumab; FDA nods to extend LILETTA’s use to prevent pregnancy; Gilead, Glympse Bio teams up to advance NASH clinical development Visit Post
189 Rapt Therapeutics files IPO; Novartis stakes $80M for NASH Visit Post
190 FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis Visit Post
191 EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline Visit Post
192 ImaginAb joins hands with AstraZeneca, Pfizer, Takeda Visit Post
193 AngioDynamics acquires Eximo; MiroBio raises USD 33 M; Janssen submits sBLA for Stelara Visit Post
194 Roche’s Tecentriq combo proves effective in Bladder cancer Visit Post
195 STipe raises USD 22M; FDA approves Darzalex for multiple myeloma Visit Post
196 EU’s labels Nirogacestat an Orphan drug; FDA Approves First Smallpox, Monkeypox Vaccine; Evotec and Takeda collaborates to discover clinical candidates Visit Post
197 Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial Visit Post
198 Boehringer Ingelheim ties up with Inflammasome Therapeutics Visit Post
199 Fujifilm acquires global rights to Cynata's novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop's digital diabetes platform Visit Post
200 AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo Visit Post
201 Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership  Visit Post
202 Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotech stake for USD 3 Billion; FDA, EMA accepts marketing of Allergan’s abicipar Visit Post
203 Vertex acquires Semma; Luxturna gets approval for rare eye disorder Visit Post
204 Helsinn out licenses Pracinostat in South America Visit Post
205 HiFiBio raises USD 67 M; FDA drafts new guidelines for Breast cancer trials; Harbour BioMed teams up with Pharmaceutical Product Development Visit Post
206 Zogenix acquires Modis Therapeutics; Amgen buys Otezla; CRISPR slows down the Breast cancer rate Visit Post
207 Themis Bioscience collaborates with Merck; Oncorus raises USD 80 M; GSK files for Japanese approval of anaemia drug Visit Post
208 Juvenescence nets USD 100M; Sarepta DMD drug faces rejection Visit Post
209 EU approval for Imbruvica; Pharming licenses orphan drug Visit Post
210 GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre Visit Post
211 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
212 Turalio gets FDA approval; Sosei Heptares, Takeda forms an R&D pact Visit Post
213 FDA approval for Nubeqa; Biodesix, Immodulon collaborates on Cancer treatment; Cancer asset rights to Alligator Bioscience Visit Post
214 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
215 Baqsimi wins FDA nod for Hypoglycemia; Freenome captures USD 160M; FDA approval for Ruxience for leukaemia Visit Post
216 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
217 PureHealth acquires LYT-100; Sosei raises USD 2.5 M Visit Post
218 Recursion Pharmaceuticals nets USD 121M; Bayer's MRI agent gets a nod Visit Post
219 Osivax raises USD 9M; Smyraf launched; Revolution secures USD 100M Visit Post
220 NICE endorsement for Pfizer’s Vizimpro; Eisai, Dundee targets Cancer; Capital raise for AgaMatrix Visit Post
221 EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline Visit Post
222 FDA's approval to Pfizer’s Zirabev; Launch of Century Therapeutics; Imbruvica's recommendation from CHMP Visit Post
223 Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan Visit Post
224 Zejula's priority review; Erytech Pharma's new facility; good news for Krystal Visit Post
225 The Business Cocktail Visit Post
226 Notizia Visit Post
227 Telegenomics nets $23M; Merck acquires Tilos; ADC nabs; Sobi buys Novoimmune's assets Visit Post
228 Notizia Visit Post
229 The Business Cocktail Visit Post
230 Notizia Visit Post
231 The Business Cocktail Visit Post
232 Notizia Visit Post
233 The Business Cocktail Visit Post
234 Notizia Visit Post
235 Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M Visit Post
236 Notizia Visit Post
237 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
238 Notizia Visit Post
239 The Business Cocktail Visit Post
240 Notizia Visit Post
241 GSK to spend $100M; Lilly sell; Sherlock Bio raises $31M; Deerfield, UIC to foster research Visit Post
242 Notizia Visit Post
243 Amgen reveals price; Bardy raises $35.5M; Kiadis to Acquire CytoSen; Insitro lands a deal Visit Post
244 Notizia Visit Post
245 Inozyme Raises $67M; Shanghai Miracogen partners with Synaffix; EdiGENE raises $15M; Antengene announces its expansion Visit Post
246 Notizia Visit Post
247 AgomAb Therapeutics raises $23.5M; Allergan's eye drug; Good news for the patients; Dyne Therapeutics comes to life Visit Post
248 Notizia Visit Post
249 The Business Cocktail Visit Post
250 Notizia Visit Post
251 The Business Cocktail Visit Post
252 Approach for Cystic Fibrosis; An alternative for Statins; Oral medications not safe; Carbon monoxide poisoning treatment gets approval Visit Post
253 BioNTech lines up $800M; Deerfield remunerates; Britain's Smith & Nephew to acquire Osiris Visit Post
254 Notizia Visit Post
255 Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering Visit Post
256 ColdZyme inactivates viruses; Med for rare genetic disease; Common oral bacteria accelerate Colon cancer; CEPI and CureVac to develop an mRNA vaccine; Celastrol’s effectiveness Visit Post
257 The Business Cocktail Visit Post
258 Notizia Visit Post
259 Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M Visit Post
260 Notizia Visit Post
261 Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets Visit Post
262 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
263 Genentech remunerates Xencor; XPrize upraises fund; GSK gambles Visit Post
264 Notizia Visit Post
265 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
266 Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial Visit Post
267 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
268 Notizia Visit Post
269 Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises Visit Post
270 Notizia Visit Post
271 Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo Visit Post
272 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
273 Atlas Venture raises; Harpoon files IPO; Boston Scientific bags Millipede Visit Post
274 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
275 Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal Visit Post
276 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
277 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
278 Notizia Visit Post
279 Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates Visit Post
280 Notizia Visit Post
281 Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal Visit Post
282 Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates Visit Post
283 Notizia Visit Post
284 Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal Visit Post
285 Notizia Visit Post
286 Triple Negative Breast Cancer Visit Post
287 Gordon and Betty Moore Foundation gives $85M; Omeicos raises; Sanofi signs deal; Lilly grabs Visit Post
288 Cholera vaccine delivered; Rice-inspired breakthroughs; International partnerships Visit Post
289 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
290 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
291 Notizia Visit Post
292 Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives Visit Post
293 Notizia Visit Post
294 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
295 Notizia Visit Post
296 COMMERCIAL AND OTHERS Visit Post
297 KEY CLINICAL OUTCOMES Visit Post
298 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
299 Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand Visit Post
300 Notizia Visit Post
301 Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner Visit Post
302 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
303 Notizia Visit Post
304 Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research Visit Post
305 Notizia Visit Post
306 Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M Visit Post
307 Notizia Visit Post
308 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
309 Notizia Visit Post
310 Commercial Visit Post
311 Clinical Visit Post
312 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
313 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
314 Notizia Visit Post
315 AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal Visit Post
316 Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates Visit Post
317 KEY CLINICAL OUTCOMES Visit Post
318 Regulatory Visit Post
319 Commercial Visit Post
320 The Business Cocktail(Therapeutics) Visit Post
321 Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup Visit Post
322 Progenics got FDA Approval; Curcumin to cancer cells Visit Post
323 Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration Visit Post
324 Business Cocktail Visit Post
325 Commercial Outcomes - Novartis Visit Post
326 Key Clinical Outcomes- 30/07/2018 Visit Post
327 Neuroscience Highlights - 17/07/2018 Visit Post
328 Oncology Highlights - 30/07/2018 Visit Post
329 Notizia Visit Post
330 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
331 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
332 Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating Visit Post
333 Business Cocktail Visit Post
334 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
335 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
336 Notizia Visit Post
337 Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients Visit Post
338 Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs Visit Post
339 Business Cocktail Visit Post
340 Business Cocktail Visit Post
341 Notizia Visit Post
342 Business Cocktail Visit Post
343 Notizia Visit Post
344 NOTIZIA Visit Post
345 The Business Cocktail : Latest Pharma deals Visit Post
346 CRISPR to cure sickle cell; FDA rejected; Stem cells use; Celgene spinoff Visit Post
347 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
348 Business Cocktail Visit Post
349 Notizia Visit Post
350 Business Cocktail Visit Post
351 Notizia Visit Post
352 Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon Visit Post
353 Notizia Visit Post
354 Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal Visit Post
355 Notizia Visit Post
356 Business Cocktail Visit Post
357 NOTIZIA Visit Post
358 Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln's anti-malarial drug Visit Post
359 Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health Visit Post
360 December 7 Business Cocktail Visit Post
361 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
362 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
363 EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit Visit Post
364 Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires Visit Post
365 Business Cocktail Visit Post
366 Teva sells generics; Valeant trades; Roche's Genentech; J&J's next potential frontier Visit Post
367 AstraZeneca and Incyte Collaborate; Tocagen’s therapy; FDA warns companies;FDA Revokes Visit Post
368 Novo petitions FDA;J&J invests; Xarelto’s trial; Roche's Tecentriq Visit Post
369 C-X-C Chemokine Receptor Inhibitors–The Emerging Therapeutic Agents Visit Post
370 Therapeutics and Celgene to develop therapies; Takeda’s expansion; J&J hopes to limit; Tech Prize for genome sequencing; Endocyte’s late-stage prostate cancer deal Visit Post
371 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
372 Business Cocktail Visit Post
373 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
374 Business cocktail Visit Post
375 Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval Visit Post
376 CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M Visit Post
377 Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults Visit Post
378 Business CockTail Visit Post
379 Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant Visit Post
380 Cannabidiol trial; MyoKardia aims; LDL drug data Visit Post
381 Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter Visit Post
382 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
383 Takeda scores; PhRMA launches; Valeant's Obagi; Ex-Novo executive signs Visit Post
384 Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down Visit Post
385 Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO Visit Post
386 Merck got attack; Stada's €5.32B; Private equity fund buys; Lonza on $5.5B deal Visit Post
387 Takeda knocks Velcade; FDA nod awaited; Novartis gets approval; Astellas UK dodges; Haegarda set for launch Visit Post
388 Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports Visit Post
389 J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials Visit Post
390 Sanofi invests; ICER pitches; $6M in NIH; Pfizer, Roche cancer drug pricing Visit Post
391 Invokana matches; Xultophy beats; Lilly and BI follow; Tresiba matches Visit Post
392 AZ offloads; Pfizer's deal; Takeda’s work on plant; Germany's doc payment Visit Post
393 Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces Visit Post
394 Tesaro’s Zejula; Mylan on EpiPen; Ohio sues drugmakers; ATUM, Horizon Discovery Announce deal Visit Post
395 Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands Visit Post
396 Merck's Remicade; Sanofi, Regeneron set Kevzara; Novartis to sever; Teva puts women's health Visit Post
397 AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer Visit Post
398 Humira’s patent; Teva laying off; GSK aims; Thermo acquires Patheon; J& J's Invokana Visit Post
399 Novartis, slammed by Korean scandal; FDA tweaks; Dendreon eyes; Amgen adds Visit Post
400 Valeant's $50M; Sanofi vows; Top pharmas team up; PhRMA expels Visit Post
401 Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out Visit Post
402 Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal Visit Post
403 FDA Approves; AZ nabs; Nordisk settles; Novartis pays Visit Post
404 Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A Visit Post
405 Samsung biosim nod sets; Lilly's med hits; BioMarin sees pricing; Spinraza scores; Klick creates Visit Post
406 Drug shortage; Fujifilm invests; Cobra Biologics to pump $19M; The world's most pricey drugs Visit Post
407 Novartis gets CAR-T drug; Shire aims to block; Xeljanz stands; Payer snubs; Lawmakers pass a bill Visit Post
408 Cancer, diabetes and eczema on list; AbbVie's Humira; Teva weighs $2B; Fresenius in buyout talks Visit Post
409 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
410 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
411 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
412 Mylan closing Illinois plant; Insys spends $24M; Roche's Ocrevus; Greece’s corruption prosecutor quits Visit Post
413 Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings Visit Post
414 Letter for AstraZeneca; Patheon on API plant; Sanofi, Regeneron’s Dupixent; Cerulean Pharma and Daré Bioscience enter into deal; Lilly on price hikes Visit Post
415 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
416 GSK consolidates DT and TT vaccine, AZ gears up for FDA filing, Novartis comes up with flex pricing, Concordia reports loss Visit Post
417 Pfizer faces patent loss; Allergan over generics probe; Sun Pharma rallies Visit Post
418 Business Cocktail Visit Post
419 NPPA slams; Japan Joins Trump; PCI Pharma Announces Expansion; Merck opens plant; Mylan and Biocon win Visit Post
420 Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition Visit Post
421 Prosecutors rope Pfizer; Pharma groups to FDA; Regeneron simulates; Otsuka & Lundbeck revive;Philidor execs plead Visit Post
422 PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch Visit Post
423 USFDA warns; Vit B3 prevents glaucoma; Zydus Cadila receives nod; U.S. experts soften on DNA editing Visit Post
424 Reckitt Acquired Mead Johnson; LabCorp’s acquisition; Ferring collaborates; J&J Licenses Visit Post
425 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
426 AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires; Renova takes over Rights Visit Post
427 FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat Visit Post
428 ALCMI, ALCF and Scancell partner; Sun unloads Ohm Labs plants; Takeda and Ovid join; Guardant and MD Anderson collaborate; Glooko and Ascensia integrate Visit Post
429 AstraZeneca announces; Trivitron launches; BrainStorm Cell Therapeutics validates Visit Post
430 Payers block EpiPen; Allergan charged; AbbVie's Humira; Baxter paying $18M Visit Post
431 U.K. weighs drug rationing; Applying Digital; FDA slaps Florida Visit Post
432 Astellas ditches UMN Pharma; J&J, Actelion land on a price; Bayer’s pledge; Biogen to fork over $1.25B-plus Visit Post
433 FDA accepts; Keytruda takes lead; M Pharmaceutical develops; Merck Deploys Palantir Visit Post
434 Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B Visit Post
435 Sanofi, Regeneron one step closer; Pharma's deal; J&J and Actelion deal Visit Post
436 Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out Visit Post
437 Pfizer uses; FDA approves; EMA approves; Mylan launches Visit Post
438 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
439 Novartis joins; Sanofi weighs Actelion; Valeant and Takeda's $10B deal; Astellas scouts pipeline Visit Post
440 Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat Visit Post
441 EC grants; Pfizer cuts; 27 medicines sold; Keytruda nabs Visit Post
442 Novartis Buys; FDA approves; Mayne Pharma Launches; Oxford Genetics Receives Grant Visit Post
443 Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal Visit Post
444 Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika Visit Post
445 Collaborate for TYG Oncology; GE Healthcare and Valneva collaboration; UPS to Acquire Marken Visit Post
446 Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan's MAA accepted; Pricing hit pharma Visit Post
447 Sun Pharma Announces Launch; OptiNose files; Opiant obtains rights; Swissmedic approves Visit Post
448 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
449 Sun Pharma & ICGEB announce collaboration; Boehringer Ingelheim and Lupin Sign deal; Daiichi Sankyo Announces; Catalent Pharma Solutions partners with Samsung Bioepis; Celltrion Healthcare and Teva enters into exclusive business collaboration agreement Visit Post
450 Merck launches Biosimilars, ABITEC announces extension, First human clinical trial, FDA awards 2grants, Corden Pharma Expands, Juniper Pharma Services Offers Visit Post
451 Bayer Partners with DelSiTech to Develop; Amgen and Arrowhead Announce; Allergan, AstraZeneca’s deal; Lexicon Pharma announces deal Visit Post
452 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
453 Bayer AG & Evotec AG’s deal; Plasticell and CellSpring AG’s deal; Allergan Acquires Akarna; Cambrex Acquires Pharmacore Visit Post
454 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
455 Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Visit Post
456 Piramal buys; Abbott Buys Glomed; Merck Divesting; Takeda set to sell; Teva gets clearance Visit Post
457 Roche's drug; Cancer drugs risk; FDA norms; Takeda sets deal Visit Post
458 Sun Pharma forms partnership; Pfizer and DCRI collaborate; Avara Acquires AZ; ASLAN Pharmaceutical’s Collaboration; Amgen and Servier partnership Visit Post
459 Treatment for esophageal cancer; FDA bans soaps; Dr Reddy's Launches; Cipla Gets Approval Visit Post
460 Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug Visit Post
461 NATCO Pharma surges; AstraZeneca falls; US patent office rules Visit Post
462 Bristol Meyers Squibb & AbbVie partner; BioLineRx’s collaboration with MD Anderson Cancer Centre; Partnership between Regeneron Pharmaceuticals and Adicet Bio; Immunotherapy Target Unique Mutations in cancer Visit Post
463 Business Cocktail Visit Post
464 Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Patent fight Visit Post
465 Notizia Visit Post
466 The Business Cocktail Visit Post
467 Rising of Orphan Drug Development Visit Post